Second‑Line CAR‑T Cell Therapy for Diffuse Large B‑Cell Lymphoma: Evidence‑Based Guidance

Historical Guideline Context

The 2019 NCCN guidelines limited CAR‑T cell therapy to patients who had received two or more prior chemo‑immunotherapy regimens, effectively restricting its use to the third line or later. [1] [2]

The European Society for Medical Oncology (ESMO) states that CAR‑T cell therapy provides superior outcomes compared with the traditional autologous stem‑cell transplantation (ASCT) pathway in patients with early‑relapsed disease. 3
In patients who relapse within 12 months after rituximab‑containing first‑line therapy, the conventional ASCT approach yields only ≈23 % three‑year progression‑free survival, highlighting the limited efficacy of the transplant strategy in this high‑risk group. 3
Recent evidence positions CAR‑T cell therapy as at least equivalent, and likely superior, to ASCT for early‑relapsed or refractory DLBCL, supporting its preferential use in this setting. 3

Candidates must have renal function with creatinine clearance ≥ 60 mL/min to be eligible for CAR‑T therapy. 3
Candidates must demonstrate cardiac ejection fraction ≥ 45 % to meet organ‑function requirements. 3

Do not proceed directly to autologous stem‑cell transplantation without first evaluating CAR‑T cell therapy in patients with early‑relapsed or refractory DLBCL, as current evidence favors CAR‑T as the preferred approach. 3
Salvage chemotherapy followed by ASCT should be reserved for patients who do not meet CAR‑T eligibility criteria or who are unsuitable for cellular therapy, ensuring that CAR‑T is considered whenever feasible. 3

CAR‑T cell therapy is not indicated for primary central nervous system (CNS) lymphoma; such cases require alternative regimens, typically high‑dose methotrexate‑based protocols. 4

Cytokine release syndrome (CRS) occurs in approximately 92 % of patients receiving axicabtagene ciloleucel, with grade ≥ 3 events in about 7 % (based on the pivotal trial data reported by the National Comprehensive Cancer Network). 5
Neurotoxicity is observed in roughly 74 % of axicabtagene ciloleucel recipients, with grade ≥ 3 events in about 25 % (derived from the same NCCN‑reported trial cohort). 6

For grade 2 or higher CRS, the recommended first‑line intervention is tocilizumab 8 mg/kg intravenously (maximum 800 mg per dose), repeatable every 8 hours if no improvement is seen; if hypotension persists despite tocilizumab, add dexamethasone 10 mg intravenously. These recommendations stem from the NCCN‑published management algorithm for axicabtagene ciloleucel. 5

The 2019 NCCN guidelines restricted CAR‑T cell therapy to patients who had already received two or more prior chemo‑immunotherapy regimens, effectively limiting its use to third‑line or later treatment. This historical recommendation reflects earlier evidence thresholds before the emergence of second‑line data. 7